Allergan near buyout deal of up to US$65b to escape Valeant, Ackman: source

Actavis may pay Botox maker between US$215 and US$220 per share

New York

ALLERGAN Inc is close to a buyout deal worth up to US$65.5 billion by Actavis plc, one that could end months of pursuit by Canada's Valeant Pharmaceuticals and William Ackman's hedge fund, Pershing Square Capital Management, according to a person familiar with the matter.

Actavis may pay Allergan between US$215 and US$220 per share, with the final price likely coming at the high end of that range, according to the source. A deal could be announced as early as Monday, the source added.

If such...

BT is now on Telegram!

For daily updates on weekdays and specially selected content for the weekend. Subscribe to